Annual Accounts Payable
$961.00 K
-$140.00 K-12.72%
December 31, 2023
Summary
- As of February 26, 2025, MRKR annual accounts payable is $961.00 thousand, with the most recent change of -$140.00 thousand (-12.72%) on December 31, 2023.
- During the last 3 years, MRKR annual accounts payable has fallen by -$1.97 million (-67.26%).
- MRKR annual accounts payable is now -81.32% below its all-time high of $5.14 million, reached on December 31, 2021.
Performance
MRKR Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$2.56 M
+$877.60 K+52.25%
September 30, 2024
Summary
- As of February 26, 2025, MRKR quarterly accounts payable is $2.56 million, with the most recent change of +$877.60 thousand (+52.25%) on September 30, 2024.
- Over the past year, MRKR quarterly accounts payable has increased by +$877.60 thousand (+52.25%).
- MRKR quarterly accounts payable is now -50.29% below its all-time high of $5.14 million, reached on December 31, 2021.
Performance
MRKR Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
MRKR Accounts Payable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -12.7% | +52.3% |
3 y3 years | -67.3% | +52.3% |
5 y5 years | -40.6% | -8.9% |
MRKR Accounts Payable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -81.3% | at low | -50.3% | +166.1% |
5 y | 5-year | -81.3% | at low | -50.3% | +166.1% |
alltime | all time | -81.3% | +2109.2% | -50.3% | >+9999.0% |
Marker Therapeutics Accounts Payable History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $2.56 M(+52.2%) |
Jun 2024 | - | $1.68 M(-13.8%) |
Mar 2024 | - | $1.95 M(+102.9%) |
Dec 2023 | $961.00 K(-12.7%) | $961.00 K(-58.3%) |
Sep 2023 | - | $2.30 M(+44.9%) |
Jun 2023 | - | $1.59 M(-44.5%) |
Mar 2023 | - | $2.86 M(+160.0%) |
Dec 2022 | $1.10 M(-78.6%) | $1.10 M(-45.5%) |
Sep 2022 | - | $2.02 M(+14.4%) |
Jun 2022 | - | $1.77 M(-64.8%) |
Mar 2022 | - | $5.02 M(-2.5%) |
Dec 2021 | $5.14 M(+75.3%) | $5.14 M(+121.2%) |
Sep 2021 | - | $2.33 M(+13.9%) |
Jun 2021 | - | $2.04 M(+8.2%) |
Mar 2021 | - | $1.89 M(-35.7%) |
Dec 2020 | $2.94 M(+195.6%) | $2.94 M(-20.6%) |
Sep 2020 | - | $3.70 M(+31.6%) |
Jun 2020 | - | $2.81 M(+69.3%) |
Mar 2020 | - | $1.66 M(+67.1%) |
Dec 2019 | $993.00 K(-38.7%) | $993.00 K(-30.8%) |
Jun 2019 | - | $1.44 M(-14.0%) |
Mar 2019 | - | $1.67 M(+3.2%) |
Dec 2018 | $1.62 M(+59.5%) | $1.62 M(-54.9%) |
Sep 2018 | - | $3.59 M(-0.2%) |
Jun 2018 | - | $3.60 M(+56.2%) |
Mar 2018 | - | $2.30 M(+126.7%) |
Dec 2017 | $1.01 M(+49.3%) | $1.01 M(-42.2%) |
Sep 2017 | - | $1.76 M(+12.6%) |
Jun 2017 | - | $1.56 M(+126.8%) |
Mar 2017 | - | $688.40 K(+1.2%) |
Dec 2016 | $680.00 K(-1.6%) | $680.00 K(-59.5%) |
Sep 2016 | - | $1.68 M(+24.6%) |
Jun 2016 | - | $1.35 M(-7.5%) |
Mar 2016 | - | $1.45 M(+110.5%) |
Dec 2015 | $691.10 K(-0.3%) | $691.10 K(-21.0%) |
Sep 2015 | - | $874.60 K(+3.8%) |
Jun 2015 | - | $842.70 K(+19.8%) |
Mar 2015 | - | $703.30 K(+1.4%) |
Dec 2014 | $693.40 K(-52.2%) | $693.40 K(+17.5%) |
Sep 2014 | - | $589.90 K(-37.3%) |
Jun 2014 | - | $940.50 K(+5.2%) |
Mar 2014 | - | $893.70 K(-38.4%) |
Dec 2013 | $1.45 M(-12.8%) | $1.45 M(+47.5%) |
Sep 2013 | - | $983.30 K(+0.3%) |
Jun 2013 | - | $980.40 K(-41.6%) |
Mar 2013 | - | $1.68 M(+1.0%) |
Dec 2012 | $1.66 M | $1.66 M(+25.2%) |
Sep 2012 | - | $1.33 M(+13.6%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2012 | - | $1.17 M(+66.7%) |
Mar 2012 | - | $701.00 K(+12.1%) |
Dec 2011 | $625.10 K(-22.8%) | $625.10 K(-39.0%) |
Sep 2011 | - | $1.03 M(+44.2%) |
Jun 2011 | - | $711.00 K(-10.6%) |
Mar 2011 | - | $795.30 K(-1.7%) |
Dec 2010 | $809.30 K(+38.0%) | $809.30 K(+23.4%) |
Sep 2010 | - | $656.00 K(+29.4%) |
Jun 2010 | - | $507.00 K(-13.3%) |
Mar 2010 | - | $584.80 K(-0.3%) |
Dec 2009 | $586.60 K(-34.0%) | $586.60 K(+19.1%) |
Sep 2009 | - | $492.60 K(+49.6%) |
Jun 2009 | - | $329.20 K(-76.5%) |
Sep 2008 | - | $1.40 M(+3.4%) |
Jun 2008 | - | $1.35 M(+8.7%) |
Mar 2008 | - | $1.25 M(+41.4%) |
Sep 2007 | - | $881.20 K(+15.4%) |
Jun 2007 | - | $763.90 K(-15.5%) |
Mar 2007 | - | $904.40 K(+1.7%) |
Dec 2006 | $889.40 K(-0.2%) | $889.40 K(+5.4%) |
Sep 2006 | - | $844.20 K(+2.3%) |
Jun 2006 | - | $825.50 K(-11.4%) |
Mar 2006 | - | $931.40 K(+4.5%) |
Dec 2005 | $891.40 K(-48.4%) | $891.40 K(-38.8%) |
Sep 2005 | - | $1.46 M(+97.2%) |
Jun 2005 | - | $738.40 K(-19.2%) |
Mar 2005 | - | $914.30 K(-47.1%) |
Dec 2004 | $1.73 M(+161.1%) | $1.73 M(+78.9%) |
Sep 2004 | - | $965.90 K(+22.2%) |
Jun 2004 | - | $790.50 K(+34.6%) |
Mar 2004 | - | $587.30 K(-11.3%) |
Dec 2003 | $661.80 K(+150.1%) | $661.80 K(-15.8%) |
Sep 2003 | - | $786.40 K(+59.5%) |
Jun 2003 | - | $492.90 K(+42.9%) |
Mar 2003 | - | $345.00 K(+30.4%) |
Dec 2002 | $264.60 K(+508.3%) | $264.60 K(-16.3%) |
Sep 2002 | - | $316.10 K(+1966.0%) |
Jun 2002 | - | $15.30 K(-88.5%) |
Mar 2002 | - | $133.00 K(+205.7%) |
Dec 2001 | $43.50 K(-91.1%) | $43.50 K(-74.5%) |
Sep 2001 | - | $170.90 K(+49.3%) |
Jun 2001 | - | $114.50 K(-46.1%) |
Mar 2001 | - | $212.50 K(-56.4%) |
Dec 2000 | $487.90 K(+356.8%) | $487.90 K(+233.5%) |
Sep 2000 | - | $146.30 K(+54.8%) |
Jun 2000 | - | $94.50 K(+22.9%) |
Mar 2000 | - | $76.90 K |
Dec 1999 | $106.80 K | - |
FAQ
- What is Marker Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Marker Therapeutics?
- What is Marker Therapeutics annual accounts payable year-on-year change?
- What is Marker Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Marker Therapeutics?
- What is Marker Therapeutics quarterly accounts payable year-on-year change?
What is Marker Therapeutics annual accounts payable?
The current annual accounts payable of MRKR is $961.00 K
What is the all time high annual accounts payable for Marker Therapeutics?
Marker Therapeutics all-time high annual accounts payable is $5.14 M
What is Marker Therapeutics annual accounts payable year-on-year change?
Over the past year, MRKR annual accounts payable has changed by -$140.00 K (-12.72%)
What is Marker Therapeutics quarterly accounts payable?
The current quarterly accounts payable of MRKR is $2.56 M
What is the all time high quarterly accounts payable for Marker Therapeutics?
Marker Therapeutics all-time high quarterly accounts payable is $5.14 M
What is Marker Therapeutics quarterly accounts payable year-on-year change?
Over the past year, MRKR quarterly accounts payable has changed by +$877.60 K (+52.25%)